- Home
- ALX vs BLFS Comparison
ALX vs BLFS Comparison
Compare ALX & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | BLFS |
|---|---|---|
| Founded | 1928 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 1989 |
Fundamental Metrics
Financial Performance| Metric | ALX | BLFS |
|---|---|---|
| Price | $241.70 | $25.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 76.8K | ★ 283.2K |
| Earning Date | 02-09-2026 | 03-02-2026 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.14 | N/A |
| Revenue | ★ $215,838,000.00 | $100,144,000.00 |
| Revenue This Year | N/A | $18.45 |
| Revenue Next Year | N/A | $16.27 |
| P/E Ratio | $34.40 | ★ N/A |
| Revenue Growth | N/A | ★ 87.53 |
| 52 Week Low | $185.75 | $19.10 |
| 52 Week High | $260.84 | $29.62 |
Technical Indicators
Market Signals| Indicator | ALX | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 68.81 | 50.37 |
| Support Level | $224.33 | $23.84 |
| Resistance Level | $250.61 | $26.54 |
| Average True Range (ATR) | 8.14 | 1.12 |
| MACD | 1.86 | 0.12 |
| Stochastic Oscillator | 79.80 | 52.43 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.